From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

Vaccine

Volumn 29, Issue 42, 2011, Pages 7229-7241

  Guy, Bruno ^a   Barrere, Beatrice ^a   Malinowski, Claire ^a   Saville, Melanie ^a   Teyssou, Remy ^a   Lang, Jean ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Dengue; Development; Human; Immunogenicity; Safety; Vaccine

Indexed keywords

DENGUE VACCINE; LIVE FLAVIVIRUS VACCINE; LIVE VACCINE; TETRAVALENT DENGUE VACCINE; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; CELLULAR IMMUNITY; CLINICAL EVALUATION; DENDRITIC CELL; DENGUE; DENGUE VIRUS; ENVELOPE GENE; EXPERIMENTAL MODEL; FLAVIVIRUS; GENETIC STABILITY; HAPLORHINI; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPATHOLOGY; MOSQUITO; NONHUMAN; PARASITE VECTOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RESEARCH; RISK ASSESSMENT; SEROTYPE; VIRAL TROPISM; VIREMIA; VIRULENCE; VIRUS STRAIN;

ANIMAL EXPERIMENTATION; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG DISCOVERY; FRANCE; HUMANS; IMMUNIZATION, SECONDARY; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; YELLOW FEVER VACCINE;

EID: 80052406004     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.094     Document Type: Article

References (80)

1. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, Suppl 12:S7-S16.
2. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587-619.
3. Bray M., Lai C.J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci USA 1991, 88(22):10342-10346.
4. Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999, 73:3095-3101.
5. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000, 74:5477-5485.
6. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
7. Guy B., Saville M., Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010, 6(9):696-705.
8. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 8:4761-4775.
9. Barban V., Girerd Y., Aguirre M., Gulia S., Pétiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007, 25:2941-2950.
10. Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., et al. High fidelity of yellow fever virus RNA polymerase. J Virol 2004, 78:1032-1038.
11. Mantel N, Girerd Y, Geny C, Bernard I, Pontvianne J, Lang J, et al., Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 2011, in press, doi:10.1016/j.vaccine.2011.06.101.
12. Hahn C.S., Dalrymple J.M., Strauss J.H., Rice C.M. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA 1987, 84(7):2019-2023.
13. Miller B.R., Atkins D. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. Acta Virol 1988, 32:227-234.
14. Vlaycheva L.A., Chambers T.J. Neuroblastma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J Virol 2002, 76:6172-6184.
15. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33:131-144.
16. Wu S.J., Grouard-Vogel G., Sun W., Mascola J.R., Brachtel E., Putvatana R., et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000, 6:816-820.
17. Libraty D.H., Pichyangkul S., Ajariyakhajorn C., Endy T.P., Ennis F.A. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 2001, 75:3501-3508.
18. Palmer D.R., Sun P., Celluzzi C., Bisbing J., Pang S., Sun W., et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 2005, 79:2432-2439.
19. Long H.T., Hibberd M.L., Hien T.T., Dung N.M., Van Ngoc T., Farrar J., et al. Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. J Infect Dis 2009, 199(4):537-546.
20. Hoang L.T., Lynn D.J., Henn M., Birren B.W., Lennon N.J., Le P.T., et al. The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. J Virol 2010, 84(24):12982-12994.
21. Brandler S., Brown N., Ermak T.H., Mitchell F., Parsons M., Zhang Z., et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 2005, 72:74-81.
22. Deauvieau F., Sanchez V., Balas C., Kennel A., de Montfort A., Lang J., et al. Innate immune responses in human dendritic cells upon infection by chimeric Yellow fever Dengue vaccines serotype 1 to 4. Am J Trop Med Hyg 2007, 76:144-154.
23. Balas C., Kennel A., Deauvieau F., Sodoyer R., Arnaud-Barbe N., Lang J., et al. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis 2011, 203(1):103-108.
24. Sanchez V., Gimenez S., Tomlinson B., Chan P.K., Thomas G.N., Forrat R., et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006, 24(23):4914-4926.
25. Warke R.V., Martin K.J., Giaya K., Shaw S.K., Rothman A.L., Bosch I. TRAIL is a novel antiviral protein against dengue virus. J Virol 2008, 82(1):555-564.
26. Daffis S., Szretter K.J., Schriewer J., Li J., Youn S., Errett J., et al. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010, 468(7322):452-456.
27. Nasirudeen A.M., Wong H.H., Thien P., Xu S., Lam K.P., Liu D.X. RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Trop Dis 2011, 5(1):e926.
28. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009, 9(10):741-747.
29. Pulendran B., Li S., Nakaya H.I. Systems vaccinology. Immunity 2010, 33(4):516-529.
30. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
31. Guy B., Barban V., Mantel M., Aguirre M., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80:302-311.
32. WHO TRS 932 Guideline for the production and quality control of candidate tetravalent dengue vaccines (live); 2003.
33. USP <1041> Biologics.
34. Ph. Eur. 0153 Vaccine for Human Use.
35. EMA/CHMP/VWP/141697/2009 Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines.
36. W HO TRS 878 Requirements for the use of animal cells as in vitro substrate for the production of biologicals.
37. FDA guidance for industry - characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications; 2010.
38. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21(2):123-132.
39. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23(45):5205-5211.
40. Edelman R., Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Summary of a WHO technical consultation. Vaccine 2008, 26(4113):4119.
41. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2:60-67.
42. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201:370-377.
43. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26:5712-5721.
44. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011, 30(1):e9-e17.
45. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29(22):3863-3872.
46. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity and Safety of a Tetravalent Dengue Vaccine in Humans. Am J Trop Med Hyg 2011; in press.
47. Durbin A.P., Schmidt A., Elwood D., Wanionek K.A., Lovchik J., Thumar B., et al. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis 2011, 203(3):327-334.
48. Green S., Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006, 19:429-436.
49. Mangada M.M., Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., Libraty D.H., et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis 2002, 185:1697-1703.
50. Mangada M.M., Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 2005, 175:2676-2683.
51. Hatch T., Endy T., Thomas S., Mathew A., Potts J., Pazoles P., et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011, 203(9):1282-1291.
52. Gunther V.J., Putnak R., Eckels K.H., Mammen M.P., Scherer J.M., Lyons A., et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 2011, 29(22):3895-3904.
53. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003, 9:921-927.
54. Dung N.T., Duyen H.T., Thuy N.T., Ngoc T.V., Chau N.V., Hien T.T., et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol 2010, 184(12):7281-7744.
55. Thomas S.J., Hombach J., Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009, 27:355-368.
56. Galan F, Forrat R, Zambrano B, Bouckenooghe A, Lang J, Dayan G. Priming effect of previous Japanese encephalitis vaccination on humoral immune response to tetravalent dengue vaccine. Presented at: American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3-7, 2010.
57. Higgs S., Vanlandingham D.L., Klingler K.A., McElroy K.L., McGee C.E., Harrington L., et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg 2006, 75:986-993.
58. Seligman S.J., Gould E.A. Live flavivirus vaccines: reasons for caution. Lancet 2004, 363:2073-2075.
59. Hombach J., Kurane I., Wood D. Arguments for live flavivirus vaccines. Lancet 2004, 364:498-499.
60. Monath T.P., Kanesa-Thasan N., Guirakhoo F., Pugachev K., Almond J., Lang J., et al. Recombination and flavivirus vaccines: a commentary. Vaccine 2005, 23:2956-2958.
61. Taucher C., Berger A., Mandl C.W. A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination. J Virol 2010, 84:599-611.
62. McGee C.E., Lewis M.G., Claire M.S., Wagner W., Lang J., Guy B., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 2008, 197:693-697.
63. McGee C.E., Tsetsarkin K., Vanlandingham D.L., McElroy K.L., Lang J., Guy B., et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 2008, 197:686-692.
64. Halstead S.B., O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977, 265:739-741.
65. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., Burke D. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989, 40:444-451.
66. Guy B., Chanthavanich P., Gimenez S., Sirivichayakul C., Sabchareon A., Begue S., et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004, 22:3563-3574.
67. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26:6077-6082.
68. Lefeuvre A. Caractérisation des interactions entre les cellules hépatiques et les souches sauvage et vaccinale du virus de la fièvre jaune: application à l'étude de virus fièvre jaune chimériques utilisés pour le développement d'un vaccin contre la dengue. Diplôme de Doctorat 2005; Université Claude Bernard Lyon 1, No 129; 2005.
69. Barban V, Mantel M, Gulia S, Girerd Y, Boaz M, Crevat D, et al. Evaluation of neutralizing antibody responses against a large range of wild-type isolates in sera of primates vaccinated with CYD TV DEN vaccine. 58th ASTM&H annual meeting Washington DC, Nov 2009. Abstract No 394.
70. Beatty M.E., Stone A., Fitzsimons D.W., Hanna J.N., Lam S.K., Vong S., et al. Asia-pacific and Americas dengue prevention boards surveillance working group. best practices in dengue surveillance: a report from the Asia-pacific and Americas dengue prevention boards. PLoS Negl Trop Dis 2010, 4(11):e890.
71. Standish K., Kuan G., Avilés W., Balmaseda A., Harris E. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl Trop Dis 2010, 4(3):e633.
72. Ramos M.M., Argüello D.F., Luxemburger C., Quiñones L., Muñoz J.L., Beatty M., et al. Epidemiological and clinical observations on patients with dengue in Puerto Rico: results from the first year of enhanced surveillance - June 2005-May 2006. Am J Trop Med Hyg 2008, 79(1):123-127.
73. Tien N.T., Luxemburger C., Toan N.T., Pollissard-Gadroy L., Huong V.T., Van Be P., et al. A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam. Trans R Soc Trop Med Hyg 2010, 104(9):592-600.
74. Suaya JA, Shepard DS, Beatty ME. Dengue: burden of disease and costs of illness. Working paper for the Scientific Working Group on Dengue Research, convened by the Special Programme for Research and Training in Tropical Diseases, Geneva, 1-5 October 2006. http://www.tropika.net/review/061001Dengue_Burden_of_disease/article.pdf.
75. Vong S., Khieu V., Glass O., Ly S., Duong V., Huy R., et al. Dengue incidence in urban and rural cambodia: results from population-based active Fever surveillance, 2006-2008. PLoS Negl Trop Dis 2010, 4(11):e903.
76. Balmaseda A., Standish K., Mercado J.C., Matute J.C., Tellez Y., Saborío S., et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 2010, 201(1):5-14.
77. Cummings D.A., Iamsirithaworn S., Lessler J.T., McDermott A., Prasanthong R., Nisalak A., et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med 2009, 6(9):e1000139.
78. Mahoney R.T., Maynard J.E. The introduction of new vaccines into developing countries. Vaccine 1999, 17(7-8):646-652.
79. Lam S.K. Dengue v2V - new global initiative supporting transition from vaccine to vaccination. Vaccine 2010, 28(9):2060-2061.
80. Mahoney R., Chocarro L., Southern J., Francis D.P., Vose J., Margolis H. Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries. PLoS Med 2011, 8(2):e1000418.